Showing results (121-130 of 159) with videos related to

Sort By:
Pageof 16
Deutsche Medizinische Wochenschrift (1946)|December 4, 2004
[The competence network "acute and chronic leukemias"]R Hehlmann, U Berger, C Aul, et al.
Der Internist|March 9, 2004
[Clinical research in the "acute and chronic leukemias"competence network ]R Hehlmann, U Berger, C Aul, et al.
Leukemia|November 1, 1992
Combined effect of very early intensification and prolonged post-remission chemotherapy in patients with AMLT Büchner, W Hiddemann, U W Schaefer, et al.
Annals of Hematology|May 1, 1997
S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromesW Verbeek, B Wörmann, P Koch, et al.
Leukemia|October 1, 1992
Flow cytometric characterization of acute myeloid leukemia: IV. Comparison to the differentiation pathway of normal hematopoietic progenitor cellsL W Terstappen, M Safford, M Unterhalt, et al.
Leukemia & Lymphoma|January 1, 1993
High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparisonW Hiddemann, C Aul, G Maschmeyer, et al.
Leukemia Research|December 8, 2017
Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMMLE Schuler, F Frank, B Hildebrandt, et al.
Leukemia|January 1, 1992
Longterm effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCGT Büchner, W Hiddemann, B Wörmann, et al.
Leukemia|July 17, 1998
Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparisonW Kern, C Aul, G Maschmeyer, et al.
Onkologie|February 1, 1989
Age related randomized comparison of sequentially applied high-dose versus intermediate dose cytosine arabinoside in combination with mitoxantrone (S-HAM) in the treatment of relapsed and refractory acute myeloid leukemia: study design and preliminary resultsW Hiddemann, C Aul, G Maschmeyer, et al.
Pageof 16